Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Journal of Clinical Hepatology ; (12): 2324-2326, 2021.
Article in Chinese | WPRIM | ID: wpr-904941

ABSTRACT

Objective To investigate HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy and its clinical significance. Methods A total of 60 patients with HBV-related hepatocellular carcinoma who were admitted to Tianjin Second People's Hospital from June 2019 to August 2020 were enrolled in this study. These patients received antiviral therapy with nucleos(t)ide analogues (NAs) for at least two years, and high-sensitivity HBV DNA detection showed a HBV RNA level of < 20 IU/mL at least twice at an interval of 3 months. Liver function, HBV serum markers, and HBV RNA level were measured for all patients. The Kruskal-Wallis H test was used for comparison between multiple groups, and the Wilcoxon rank-sum test was used for comparison between two groups; a Pearson correlation analysis was used to investigate the influencing factors for HBV RNA. Results Among the 60 patients with HBV-related hepatocellualr carcinoma who received long-term antiviral treatment, 9 (15%) tested positive for HBV RNA. According to the level of alpha-fetoprotein (AFP), the patients were divided into AFP positive group and AFP negative group, and there was no significant difference in HBV RNA level between the two groups [0(0-3.57) vs 0(0-2.00), Z =-1.474, P =0.141). According to Barcelona Clinic Liver Cancer (BCLC) stage, they were divided into BCLC stage A group and BCLC stage B+C+D group, and there was no significant difference in HBV RNA level between the two groups [0(0-2.0) vs 0(0-2.0), Z =-0.607, P =0.544]. According to HBeAg level, the patients were divided into HBeAg positive group and HBeAg negative group, and there was a significant difference in HBV RNA level between the two groups [2.99(0-4.80) vs 0(0-0.50), Z =-3.400, P =0.001]. According to the titer of HBsAg, they were divided into HBsAg≤100 IU/mL group, 100 IU/mL < HBsAg < 1500 IU/mL group, and HBsAg ≥1500 IU/mL group, and there was a significant difference in HBV RNA level between the three groups [0(0-0.0) vs 0(0-0.20) vs 2.00(0.0-4.54), H =-7.899, P =0.019]. A Pearson correlation analysis was performed for age, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, alpha-fetoprotein, HBsAg, and HBeAg, and the results showed that HBsAg level was correlated with HBV RNA quantification ( r =0.292, P < 0.05). Conclusion In patients with HBV-related hepatocellualr carcinoma receiving long-term antiviral therapy with NAs, HBV RNA can still be detected after HBV DNA is lower than the lower limit of detection. HBsAg titer may be correlated with serum HBV RNA level.

2.
Journal of Clinical Hepatology ; (12): 2324-2326, 2021.
Article in Chinese | WPRIM | ID: wpr-904891

ABSTRACT

Objective To investigate HBV RNA level in patients with HBV-related hepatocellular carcinoma after long-term antiviral therapy and its clinical significance. Methods A total of 60 patients with HBV-related hepatocellular carcinoma who were admitted to Tianjin Second People's Hospital from June 2019 to August 2020 were enrolled in this study. These patients received antiviral therapy with nucleos(t)ide analogues (NAs) for at least two years, and high-sensitivity HBV DNA detection showed a HBV RNA level of < 20 IU/mL at least twice at an interval of 3 months. Liver function, HBV serum markers, and HBV RNA level were measured for all patients. The Kruskal-Wallis H test was used for comparison between multiple groups, and the Wilcoxon rank-sum test was used for comparison between two groups; a Pearson correlation analysis was used to investigate the influencing factors for HBV RNA. Results Among the 60 patients with HBV-related hepatocellualr carcinoma who received long-term antiviral treatment, 9 (15%) tested positive for HBV RNA. According to the level of alpha-fetoprotein (AFP), the patients were divided into AFP positive group and AFP negative group, and there was no significant difference in HBV RNA level between the two groups [0(0-3.57) vs 0(0-2.00), Z =-1.474, P =0.141). According to Barcelona Clinic Liver Cancer (BCLC) stage, they were divided into BCLC stage A group and BCLC stage B+C+D group, and there was no significant difference in HBV RNA level between the two groups [0(0-2.0) vs 0(0-2.0), Z =-0.607, P =0.544]. According to HBeAg level, the patients were divided into HBeAg positive group and HBeAg negative group, and there was a significant difference in HBV RNA level between the two groups [2.99(0-4.80) vs 0(0-0.50), Z =-3.400, P =0.001]. According to the titer of HBsAg, they were divided into HBsAg≤100 IU/mL group, 100 IU/mL < HBsAg < 1500 IU/mL group, and HBsAg ≥1500 IU/mL group, and there was a significant difference in HBV RNA level between the three groups [0(0-0.0) vs 0(0-0.20) vs 2.00(0.0-4.54), H =-7.899, P =0.019]. A Pearson correlation analysis was performed for age, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, alpha-fetoprotein, HBsAg, and HBeAg, and the results showed that HBsAg level was correlated with HBV RNA quantification ( r =0.292, P < 0.05). Conclusion In patients with HBV-related hepatocellualr carcinoma receiving long-term antiviral therapy with NAs, HBV RNA can still be detected after HBV DNA is lower than the lower limit of detection. HBsAg titer may be correlated with serum HBV RNA level.

3.
China Journal of Chinese Materia Medica ; (24): 1520-1522, 2009.
Article in Chinese | WPRIM | ID: wpr-344590

ABSTRACT

<p><b>OBJECTIVE</b>To study the chemical constituents from Centipeda minima.</p><p><b>METHOD</b>The constituents were isolated by column chromatography on silica gel, Sephadex LH-20 and HPLC-ODS, and identified by spectroscopic methods.</p><p><b>RESULT</b>Ten compounds, (-)-cis-chrysanthenol-O-beta-D-glucopyranoside (1), methy 3,5-dicaffeoylquinate (2), 3,5-di-O-caffeoyl quinicacid (3), tricin (4), 2-amino-4-methyl-pentanoicacid (5), 2-amino-3-phenyl-propionic acid (6), 4-amino-4-carboxychroman-2-one (7), brevilin-A (8), arnicolide C (9), arnicolide D (10) were isolated and identified.</p><p><b>CONCLUSION</b>Compounds 1-7 were isolated from the plant for the first time.</p>


Subject(s)
Asteraceae , Chemistry , Drugs, Chinese Herbal
4.
Chinese Traditional and Herbal Drugs ; (24)1994.
Article in Chinese | WPRIM | ID: wpr-578717

ABSTRACT

Objective To study the chemical constituents of Ranunculus ternatus.Methods The constituents were isolated and purified by column chromatographic methods.Their structures were elucidated by physicochemical properties and spectral analyses.Results Nine compounds were obtained and identified as robustaflavone-4′-methyl ether(Ⅰ),kayaflavone(Ⅱ),podocarpusflavone A (Ⅲ),bilobetin(Ⅳ),isoginkgetin(Ⅴ),amentoflavone(Ⅵ),4-oxo-5-(O-?-D-glucopyranosyl)-pentanoic acid-1O-butyl ester(Ⅶ),4-oxo-5-(O-?-D-glucopyranosyl)-pentansaeure-methyl ester(Ⅷ),benzyl alcohol O-?-D-glucopyranoside(Ⅸ).Conclusion Compounds Ⅰ-Ⅵ are obtained from the plants of Ranunculus Linn.for the first time,compound Ⅷ is a new natural product and compound Ⅸ is obtained from this plant for the first time.

SELECTION OF CITATIONS
SEARCH DETAIL